Table 2.
Lipid-based miRNA delivery systems.
| Delivery System | miRNA | Therapeutic Application |
Lipids Used | Particle Size | Refs. |
|---|---|---|---|---|---|
| Liposomes/ Lipoplexes |
anti-miR-21 | Lung cancer | DODMA/DOTAP/ DOPC/CHOL/mPEG-DPPE |
150 nm | [65] |
| miR-603 | Glioblastoma | DOTAP/DOTMA/ DC-CHOL |
120–160 nm | [58] | |
| miR-29b | Lung cancer | DOTMA | 84 nm | [81] | |
| miR-133a | Glioblastoma | KLN25/MM27 | 180.9 nm | [79] | |
| miR-499 | Cancer | DPPC/DOPE/ CHOL/DCP-TEPA |
200 nm | [82] | |
| miR-101 | Acute myeloid leukemia | DPPC/DOTAP/CHOL/ mPEG2000-DSPE |
126.6 nm | [83] | |
| miR-101 | Hepatocellular carcinoma | DOTAP | 150 nm | [84] | |
| SLNs | anti-miR-21 | Glioblastoma | DDAB/tristearin/glyceryl tripalmitate/1-α-Phosphatidylcholine | 124.9 nm | [69] |
| miR-34a | Lung cancer | DDAB/Glyceryl monostearate/Soy phosphatidylcholine/CHOL | 220 nm | [70] | |
| LPP | miR-29b | Acute myeloid leukemia | DOPE/linoleic acid/DMG-PEG | 137–147 nm | [72] |
| miR-133a | Glioblastoma | KLN25/MM27 | 117.9 nm | [79] |
Abbreviations: DODMA: 1,2-dioleyloxy-3-dimethylaminopropane; DOTAP:1,2-dioleoy-1-3- trimethylamonium propane; DOPC: 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine; CHOL: cholesterol; DPPE: 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine; DOTMA: N-[1-(2,3-dioleyloxy) propyl-N,N,N-trimethylammonium chloride; DC-CHOL: 3β-[N-(Dimethylaminoethane)carbamoyl]cholesterol; DMG-PEG: 1,2-dimyristoylsn-glycerol, methoxypolyethylene glycol KLN25: O,O-dioleyl-N-[3 N-(N-methylimidazolium iodide) propylene] phosphoramidate; MM27: O,O-dioleyl-N-histamine phosphoramidate; DOPE: dioleoylphosphatidyl ethanolamine; DCP-TEPA: dicetyl phosphate-tetraethylenepentamine; DPPC: dipalmitoylphosphatidylcholine; mPEG2000-DSPE: monomethoxy polyethylene glycol 2000-distearoyl phosphatidylethanolamine; DDAB: dimethyldioctadecylammonium bromide.